Phase 1b/2 Study Evaluates WTX-330 Dosing Regimens in Advanced Solid Tumors and NHL

Werewolf Therapeutics is assessing WTX-330, an IL-12 peptide prodrug, using both fixed and step-up dosing regimens in a multisite study targeting advanced/metastatic solid tumors and non-Hodgkin lymphoma. The trial aims to determine the maximum tolerated and recommended expansion doses while evaluating antitumor activity, pharmacokinetics, and immune biomarker changes across multiple disease cohorts including melanoma, MSS colorectal cancer, and NHL.